Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
Paula DavidOr HenNiv Ben-ShabbatTom MacleodHoward AmitalAbdulla WatadDennis G McGonaglePublished in: RMD open (2024)
The efficacy of baricitinib in COVID-19 pneumonia is linked to obesity suggesting that immunomodulatory therapy benefit is associated with obesity-associated inflammation.
Keyphrases
- weight loss
- coronavirus disease
- metabolic syndrome
- sars cov
- insulin resistance
- type diabetes
- high fat diet induced
- weight gain
- adipose tissue
- bariatric surgery
- oxidative stress
- body mass index
- intensive care unit
- community acquired pneumonia
- bone mineral density
- stem cells
- skeletal muscle
- postmenopausal women
- physical activity
- extracorporeal membrane oxygenation